Biotech Startups

Developed site-specific protein conjugation and linker technologies; acquired by Catalent Pharma Solutions in 2014.

1 investor

REEgen uses genetically engineered bacteria to recover rare earth elements and critical metals from ores and industrial by-products such as steel slag, electronic waste, spent catalysts, and coal ash. The bioleaching process aims to provide a cleaner, circular alternative to conventional rare earth extraction and diversify a supply chain currently dominated by China.

1 investor

ReEmerge develops Cognitive Network Restoration Therapy (CNRT), a thalamic deep brain stimulation approach that targets disrupted neural networks to restore cognitive function in patients with traumatic brain injury. The company aims to move cognitive care beyond rehabilitation toward actively restoring impaired brain function.

1 investor

ReenBio is an ingredient biotechnology company that uses precision fermentation, enzymatic bioconversion and upcycled crop-residue feedstocks to produce natural ingredients that are molecularly identical to crop-derived vanilla, coffee and cocoa. It supplies drop-in replacement ingredients, recovered flavour aromatics and nutraceutical actives to food, beverage, cosmetics and healthcare manufacturers.

1 investor

Rees Scientific manufactures centralized monitoring systems for facilities, including hardware platforms and cloud-based solutions for tracking critical equipment and environmental conditions. The company serves industrial and facility management operations requiring compliance, scalability, and remote monitoring capabilities.

1 investor

Reference Medicine supplies biological specimens to researchers and diagnostics developers working on cancer diagnostic tools. The company sources materials to support biotech and life sciences research.

1 investor

Refoxy is a science-driven company focused on drug discovery, medicinal chemistry, and bioinformatics. The team page emphasizes deep science and collaboration, but the page provides only placeholder text about the company's specific work.

1 investor

Regatta Bio develops precision regulatory T-cell (Treg) therapies aimed at inducing immune tolerance for patients with immune-driven conditions such as chronic graft-versus-host disease, transplant rejection, autoimmune diseases, and inflammatory conditions. The company positions its approach as an alternative to broad immunosuppression across cell transplants, organ transplants, and autoimmunity.

1 investor

Regenity Biosciences is a contract development and manufacturing organization (CDMO) specializing in bioresorbable medical devices made from collagen and synthetic polymers for soft and hard tissue regeneration. It partners with medical technology companies—from startups to large healthcare firms—to design, develop, and manufacture regenerative therapies and implants.

1 investor

Regenosca develops TissueSpan, an absorbable mesh implant that prompts the body to attract and organize its own cells for soft tissue regeneration, reinforcing or replacing damaged tissue. Its initial target application is urethral stricture repair, with potential use across a range of regenerative surgical interventions.

1 investor

Regentis Biomaterials develops regenerative medicine products for tissue repair, focused on orthopedic cartilage and bone treatments through its Gelrin degradable hydrogel platform. Its lead product, GelrinC, is a cell-free hydrogel implant for repairing articular knee cartilage injuries, CE-marked in Europe and in US clinical trials toward PMA approval.</parameter> <parameter name="founders">[]

1 investor

Reglagene develops a brain-penetrant oral drug therapy designed to treat primary tumors and brain metastases in patients with cancer. The company focuses on CNS oncology, targeting a mechanism validated in solid tumors but previously unexploited for brain-penetrant therapies.

1 investor

REKAH Pharmaceutical Industries is an Israeli manufacturer of generic pharmaceuticals, cosmetics, vitamins, nutritional supplements, and medical devices, with subsidiaries handling production, R&D, marketing, sales, distribution, and international expansion.

1 investor

BEAUTE DE LABO develops and supplies beauty treatment products and services for women, with a focus on skincare and professional training. The company operates training centers across Japan and sells products through a network of licensed beauty salons and advisors.

1 investor

Relevium Medical is a biopharmaceutical company developing long-lasting treatments for chronic pain conditions, particularly osteoarthritis. The company focuses on therapeutic hydrogels and drug discovery for patients with debilitating pain.

1 investor

RELISTOR is a prescription medication containing methylnaltrexone bromide that treats opioid-induced constipation in adults with chronic pain or advanced illness. The drug is available in tablet and injection forms and is marketed for patients requiring pain management with opioids.

1 investor

Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation. Its programs address indications such as bladder cancer and Prader-Willi syndrome.

1 investor

Ren BioScience develops small-molecule therapies aimed at preserving organ function, including an oral lead compound for inherited retinal diseases and preclinical programs targeting acute kidney injury and mitochondrial-driven metabolic and autoimmune conditions. Its focus is on protecting cells from irreversible injury across ophthalmic, renal, and metabolic disease areas.

1 investor

Renerva develops implantable medical devices to treat peripheral nerve injuries. The company was founded from academic research at the University of Pittsburgh and Cornell University.

1 investor

ReNerve develops nerve repair products, including cuffs, grafts, and bionic nerve structures, to treat transected nerves and improve patient outcomes. The company operates research laboratories in Melbourne, Australia, and collaborates with researchers at the CSIRO / Monash University biomaterials precinct.

1 investor

Renova Therapeutics develops investigational gene therapies intended as single-dose, long-lasting treatments for common chronic diseases, with an initial focus on congestive heart failure and type 2 diabetes. The company builds a platform of therapeutics and delivery systems based on proprietary insights into disease mechanisms.

1 investor

Renovion develops ARINA-1, a next-generation mucolytic therapy delivered as a sterile buffered ascorbic acid and glutathione solution to the lungs. The therapy targets chronic inflammatory airway diseases affecting over 170 million patients globally, including non-cystic fibrosis bronchiectasis, chronic bronchitis, COPD, and asthma.

1 investor

Renovo Solutions operates a Life Sciences business line providing services and solutions to pharmaceutical, biotech, medical device, and laboratory services companies.

1 investor

RenovoDerm is a life sciences company developing wound care and tissue technology platforms within the medtech and biotech sectors. It operates as a commercial subsidiary of Paragen Technologies.

1 investor